Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.60 |
| ▸ | NCF1 | P14598 | 10/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690490 | 0.78 | NCF1 (0.64) | BACE1NCF1MAOAKDM4EALDH1A1 | |
| SCHEMBL29420516 | 0.78 | MAOA (0.54) | MAOAKDM4EALDH1A1GLAHPGD | |
| SCHEMBL397020 | 0.78 | MAOA (0.54) | MAOAKDM4EALDH1A1GLAHPGD | |
| SCHEMBL323374 | 0.78 | NCF1 (0.64) | BACE1NCF1MAOAKDM4EALDH1A1 | |
| SCHEMBL5640307 | 0.78 | NR4A2 (0.53) | BACE1ACHECHRM1LMNATP53 | |
| SCHEMBL832716 | 0.76 | BACE1 (0.56) | BACE1NCF1MAOAKDM4EALDH1A1 | |
| SCHEMBL482375 | 0.75 | BACE1 (0.60) | BACE1NCF1MAOAKDM4EALDH1A1 | |
| SCHEMBL31667822 | 0.75 | BACE1 (0.60) | BACE1NCF1MAOAKDM4EALDH1A1 | |
| SCHEMBL3094768 | 0.75 | BACE1 (1.00) | BACE1NCF1MAOAKDM4EALDH1A1 | |
| SCHEMBL2950892 | 0.75 | BACE1 (0.60) | BACE1NCF1MAOAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010330-B1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | HIRUNDO BIOSCIENCES (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225750-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3618829-B1 | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3618829-B1 | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-110612100-B | Quinazoline-pyridine derivatives for the treatment of diseases associated with cancer | 艾库斯生物科学有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2022-12-08 | — | — | US | disclosed |
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2022-12-08 | — | — | US | disclosed |
| US-6339093-B1 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-01-15 | — | — | US | disclosed |
| EP-1090917-A1 | Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| CN-1290698-A | Quinoline-4-base deviative I | HOFFMANN LA ROCHE (CH) | 2001-04-11 | — | — | CN | disclosed |
| EP-1088818-A1 | Quinolin-4-yl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| US-4279912-A | ANTIALLERGENS, BRONCHODILATORS | ROUSSEL UCLAF (FR) | 1981-07-21 | — | — | US | disclosed |
| US-4075343-A | Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof | PFIZER INC. (US) | 1978-02-21 | — | — | US | disclosed |
| US-4066766-A | 1-Oxo-6-substituted pyrimido [1,2-a]quinoline-2-carboxylic acids and derivatives thereof and their use as antiallergy agents | PFIZER INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4031217-A | PYRIMIDINE-QUINOLINE COMPOUNDS | PFIZER INC. (US) | 1977-06-21 | — | — | US | disclosed |
| US-4017625-A | Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor | PFIZER INC. (US) | 1977-04-12 | — | — | US | disclosed |
| US-4014881-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABL1, PHKB, EEF2K | BACE1 3682/4885NCF1 1153/4885MAOA 3238/4885 |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | BACE1 4670/4885NCF1 990/4885MAOA 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.